Abstract 1054P
Background
Patients who have been cured of a first primary lung cancer (FPC) are at increased risk of developing a second primary cancer (SPC). It is currently unknown whether immunotherapy with immune checkpoint inhibitors (ICIs) impacts the risk of developing an SPC. Primary objective: To analyze the risk of second malignancies according to treatment received over time.
Methods
Patients were collected through the Thoracic Tumor Registry (TTR) of Spain, an ongoing multicenter prospective registry, where patients are included and followed with an observational nature and nationwide coverage (81 centers over Spain participate). Start of recruitment: August 2016. Time of data extraction: March 2023, with 26,149 patients enrolled. Comparison of treatment groups: χ2 test for categorical variables and ANOVA for quantitative variables. Second malignancy-free survival (Events = presence of a second malignancy or death): Kaplan-Meier method. Comparison survival curves: log-rank test with Benjamini & Hochberg correction method. Median follow-up times: reverse Kaplan-Meier method.
Results
485 p developed SCP and the median follow-up time for the patients included was 40.6 months. The incidence of SPC is higher in chemotherapy group (2.9%) compared to immunotherapy group (2.1%) and targeted therapy group (1.5%) (p <0.001). Median treatment time is shorter in chemotherapy group (71 days) than in immunotherapy group (179 days) and targeted therapy group (236 days) (p<0.001). The hazard ratio (HR) to develop SCP of immunotherapy and targeted therapy with respect to chemotherapy is HR=0.715 (95%CI 0.688-0.744) and HR=0.688 (95%CI 0.651-0.726), respectively.
Conclusions
Patients treated with immunotherapy for lung cancer have a lower hazard ratio to develop SPC than patients treated with chemotherapy. Patients in the chemotherapy group develop more SPC even though they have a shorter treatment exposure time and a shorter or similar follow-up time than targeted therapy or immunotherapy, respectively.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fundacion GECP, Spanish Lung Cancer Group.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
927P - Preliminary results of the BROADEN study: Burden of human papillomavirus-related head and neck cancers
Presenter: Laia Alemany
Session: Poster session 03
928P - Radiomic analysis based on machine learning of multi-MR sequences to assess early treatment response in locally advanced nasopharyngeal carcinoma
Presenter: Lei Qiu
Session: Poster session 03
929P - Advanced laryngeal squamous cell carcinoma prognosis and machine learning insights
Presenter: Tala Alshwayyat
Session: Poster session 03
Resources:
Abstract
930P - Real-world data analysis of oncological outcomes in patients with pathological extranodal extension (ENE) in OSCC: A proposal to refine the pathological nodal staging system
Presenter: Abhinav Thaduri
Session: Poster session 03
931P - Deep learning models for predicting short-term efficacy in locally advanced nasopharyngeal carcinoma
Presenter: Kexin Shi
Session: Poster session 03
932P - Accuracy and prognostic implications of extranodal extension on radiologic imaging in HPV-positive oropharyngeal cancer (HNCIG-ENE): A multinational, real-world study
Presenter: Hisham Mehanna
Session: Poster session 03
933P - Prediction of survival in patients with head and neck merkel cell carcinoma: Statistical and machine-learning approaches
Presenter: Jehad Yasin
Session: Poster session 03
934P - Harnessing artificial intelligence on real-world data to predict recurrence in head and neck squamous cell carcinoma patients: The HNC-TACTIC study
Presenter: Hisham Mehanna
Session: Poster session 03
936P - Chronic pain in cancer survivors: Head and neck versus other cancers
Presenter: Rong Jiang
Session: Poster session 03